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Tourette syndrome (TS) and obsessive-compulsive disorder (OCD) both are neuropsychiatric
disorders associated with abnormalities in dopamine neurotransmission. Aims of this study were
to quantify striatal D2/3 receptor availability in TS and OCD, and to examine dopamine release
and symptom severity changes in both disorders following amphetamine challenge.
Changes in [11C]raclopride binding potential (BPND) were assessed using positron emission
tomography before and after administration of D-amphetamine (0.3 mg kg1) in 12 TS patients
without comorbid OCD, 12 OCD patients without comorbid tics, and 12 healthy controls. Main
outcome measures were baseline striatal D2/3 receptor BPND and change in BPND following
amphetamine as a measure of dopamine release.
Voxel-based analysis revealed signiﬁcantly decreased baseline [11C]raclopride BPND in bilateral
putamen of both patient groups vs. healthy controls, differences being more pronounced in the
TS than in the OCD group. Changes in BPND following amphetamine were not signiﬁcantly
different between groups. Following amphetamine administration, tic severity increased in the
TS group, which correlated with BPND changes in right ventral striatum. Symptom severity in theElsevier B.V. and ECNP. All rights reserved.
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(D. Denys).
D. Denys et al.1424OCD group did not change signiﬁcantly following amphetamine challenge and was not
associated with changes in BPND.
This study provides evidence for decreased striatal D2/3 receptor availability in TS and OCD,
presumably reﬂecting higher endogenous dopamine levels in both disorders. In addition, it
provides the ﬁrst direct evidence that ventral striatal dopamine release is related to the
pathophysiology of tics.
& 2013 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Tourette syndrome (TS) is a neuropsychiatric disorder char-
acterized by the presence of vocal and motor tics (Robertson,
2000). Obsessive-compulsive disorder (OCD) is an anxiety
disorder characterized by obsessions that cause anxiety, and
compulsions aimed at reducing that anxiety (Leckman et al.,
2010). There is considerable overlap between the two dis-
orders in terms of clinical phenomenology, epidemiology,
genetics, immunology, and treatment (Ferrao et al., 2009).
Despite these commonalities, it is still not clear to which
extent pathogenetic mechanisms in TS and OCD are similar,
although it has been assumed that abnormalities in dopami-
nergic (DA) neurotransmission within fronto-striatal circuitry
are of key importance in both disorders (Gerard and Peterson,
2003; Denys et al., 2004).
The dopamine hypothesis of TS and OCD is based predomi-
nantly on clinical evidence and molecular imaging studies. For
example, dopamine receptor antagonists are effective as
monotherapy in reducing tics in TS (Robertson, 2000) and as
an adjunct to SSRIs in reducing symptoms in OCD (Denys, 2006;
Vulink et al., 2009). Moreover, dopamine agonists may provoke
tics (Lowe et al., 1982; Borcherding et al., 1990) and induce
obsessive-compulsive behavior (Borcherding et al., 1990;
Lemus et al., 1991). Molecular imaging studies using radio-
tracers binding to DA receptors have yielded conﬂicting results
in TS (Gerard and Peterson, 2003). Some studies have
supported the hypothesis that DA receptors are involved
(Albin et al., 2003; Gilbert et al., 2006; Singer et al., 2002;
Wong et al., 1997, 2008), other studies failed to show
differences (Albin et al., 2009; George et al., 1994; Meyer
et al., 1999; Turjanski et al., 1994). There are only a few
reports on DA receptor binding in OCD, but these consistently
have shown evidence for decreased D2 receptor availability
(Denys et al., 2004; Olver et al., 2009; Perani et al., 2008).
The inconsistencies in previous molecular imaging studies
in TS may be explained by a number of methodological
factors, including limited power of positron emission tomo-
graphy (PET) and single photon emission computerized
tomography (SPECT) studies, heterogeneity within subject
populations, especially with regard to symptom severity and
co-morbidity, and changes in DA receptor expression and/or
function due to the clinical use of DA antagonists.
In the present study, we aimed to elucidate the role of DA
neurotransmission in TS and OCD using the extensively
validated PET tracer [11C]raclopride (Gunn et al., 1997;
Lammertsma et al., 1996). [11C]raclopride binds to D2/3
receptors and may be used to evaluate in vivo receptor
binding at rest, as well as capture more dynamic aspects of
DA transmission. Indeed, the change in [11C]raclopridebinding following amphetamine challenge, which increases
endogenous DA levels, is considered an indirect measure of
DA release (Laruelle, 2000; Spitzer et al., 1992). Further-
more, amphetamine administration has been associated
with induction of tics and compulsive behaviors, especially
when high doses are used (Borcherding et al., 1990; Caste-
llanos et al., 1997). Consequently, measuring changes in
[11C]raclopride following amphetamine administration in TS
and OCD patients may serve as a measure of symptom
related DA release.
Two previous studies using this paradigm reported
increased [11C]raclopride displacement in the putamen in
a sample of 5 TS patients (Laruelle, 2000; Singer et al.,
2002) and, in an extended sample of 14 TS patients and 10
control subjects in the right ventral striatum (Laruelle,
2000; Wong et al., 2008). The majority of patients in the
second study, however, had a co-morbid diagnosis of OCD,
which in itself may be associated with abnormalities in DA
neurotransmission.
The purpose of the present study was to directly com-
pare baseline availability of striatal D2/3 receptors and
amphetamine-induced DA release between TS patients without
OCD, OCD patients without tics or TS, and healthy controls.
2. Experimental procedures
2.1. Subjects
Patients were recruited through referrals from the academic out-
patient clinic for anxiety disorders of the Academic Medical Center
(AMC) Amsterdam and GGZinGeest, Amsterdam. Healthy control
subjects were recruited through advertisements.
All subjects were interviewed by trained psychiatrists and diagnoses
were conﬁrmed using the Structural Clinical Interview for DSM-IV axis I
disorders (SCID-I) (Spitzer et al., 1992). Tic history and severity were
assessed using the Yale Tic Symptom Check List and the Yale Global Tic
Severity Scale (YGTSS) (Leckman et al., 1989) and obsessive-
compulsive symptoms using the Yale Brown Obsessive Compulsive
Scale (YBOCS) (Goodman et al., 1989). Affective symptoms were
assessed using the Hamilton Depression (HAM-D) and Anxiety (HAM-A)
rating scales. Control subjects were included when there was no
current or past psychiatric diagnosis. All subjects were free of
psychotropic medication for at least 6 months. Nine TS subjects never
had taken medication for their tics. One subject had used antipsycho-
tic medication until 1 year before the study and two subjects had used
an alpha2 agonist several years before inclusion. Seven OCD subjects
had never used medication for their obsessive-compulsive symptoms,
whereas ﬁve had used SSRIs until 6 months before the study. Two TS
subjects and three OCD subjects had a history of co-morbid depressive
episodes, and one OCD subject had a co-morbid panic disorder.
Subjects were excluded when they had a history of regular use of
psychoactive drugs or a positive urine drug screen, a history of
neurological disease, or more than one risk factor for cardiovascular
1425Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorderdisease. All subjects were in good physical health, based on medical
history, physical examination, electrocardiogram, MRI of the brain and
routine blood screening. Written informed consent from all subjects
was obtained after a complete description of the study. Medical ethics
committees of all participating centers approved the study protocol.
2.2. Radiochemistry
[11C]raclopride was prepared as previously described (Bossong
et al., 2009), in accordance with the EU guideline “Eudralix volume
4: good manufacturing practices”. The precursor O-desmethyl
raclopride hydrobromide was provided by ABX, Radeberg, Germany.
2.3. PET procedure
PET scans were performed using an ECAT EXACT HR+ (Siemens/CTI,
Knoxville, TN, USA), which acquires 63 transaxial planes with an axial
ﬁeld of view of 15.5 cm, covering the entire brain. [11C]raclopride was
delivered intravenously using a computerized infusion pump (MedRad,
Beek, the Netherlands). A priming bolus of 28 mL, administered over
3.1 min, was followed by a constant infusion over 88 min at a rate of
0.15 mL min1, resulting in a bolus to infusion ratio (Kbol) of 112 min
(Carson et al., 1997). Mean injected dose was similar for controls, TS
patients and OCD patients (7087125, 757743 and 7567101 MBq,
respectively; p40.1). Forty minutes after start of [11C]raclopride
administration, subjects were placed in the PET camera for a 40 min
scanning period, consisting of 8 consecutive frames of 5 min. After
emission scanning a 10 min transmission scan was performed to correct
for photon attenuation. Correction for emission contamination was
performed using the dwell proﬁle method (van der Weerdt et al.,
2004). During scanning, subjects were immobilized with a custom
made head holder. Subject motion was monitored continuously using
laser beams, and corrected immediately when necessary. After the
ﬁrst PET scan, subjects could rest outside the camera for approxi-
mately 2 h to allow for decay of carbon-11. Before the second
scanning session, amphetamine (0.3 mg kg1) was given intravenously
over 2 min, directly followed by [11C]raclopride administration. The
protocol for the second scanning session was identical to that of the
ﬁrst. Subjects were under constant cardiovascular monitoring duringTable 1 Baseline characteristics of all subjects.
Tourette's
syndrome
Obsessive-
compulsive
disorder
H
Mean Range SD Mean Range SD M
Age 31 20–45 8.1 35.8 21–56 11.5 3
Sex (male/female) 8/4 4/8 4
Number of current
tics (0–37)
10.7 4–23 6.2 0 0 0 0
YGTSS (0–50) 17.0 7–28 7.8 0 0 0 0
YBOCS (0–40) 5.1 0–15 5.5 23.6 12–32 5.5 0
Hamilton Depression
Rating Scale (0–68)
2.1 0–8 2.6 10.7 4–26 7.1 1
Hamilton Anxiety Rating
Scale (0–56)
2.9 0–16 4.7 13.9 2–34 9.4 0
YGTSS=Yale Global Tic Severity Scale.
YBOCS=Yale Brown Obsessive Compulsive Scale.
aChi-square.both scans. Measurements of symptom severity were performed
before and after administration of amphetamine, while subjects were
still outside the scanner. Both YBOCS and YGTSS were administered
immediately before injection, 20 min after injection of [11C]raclo-
pride, and after completion of the scan (120 min after injection).
Forty minutes after amphetamine administration, a venous sample
was collected to assess amphetamine plasma levels using a procedure
based on liquid chromatography–mass spectrometry (LC–MS). Amphe-
tamine plasma levels were similar across groups (controls
48.3710.2 μg/L, TS 51.4712.6 μg/L, OCD 50.577.1 μg/L, p=0.77).
All [11C]raclopride scans were reconstructed using FORE+2D FBP with a
0.5 Hanning ﬁlter, resulting in a transaxial spatial resolution of 7 mm
full width at half maximum (FHWM) in the center of the ﬁeld of view.2.4. Magnetic resonance imaging procedure
Structural T1 weighted MRI scans were acquired for all subjects on
an Intera (Philips, Best, the Netherlands) 3T scanner (echo time,
4.6 ms; repetition time, 30 ms; ﬂip angle, 301; resolution,
0.89 0.89 1 mm3).2.5. Data analysis
Non-displaceable binding potential (BPND) of [
11C]raclopride (Innis
et al., 2007) was used as measure of D2/D3 receptor availability.
Primary outcome parameters were baseline BPND and the reduction in
BPND (ΔBPND) induced by amphetamine. BPND was deﬁned as the
distribution volume ratio (DVR) minus one (Lammertsma et al., 1996).
As scans were performed during steady state, DVR corresponds with
the ratio between activity concentrations in target (CT) and reference
(CCBL) tissues. Cerebellum, which is devoid of D2/D3 receptors, was
used as reference tissue. Each PET frame was individually co-
registered to the structural T1 scan to correct for motion between
frames. For both baseline and amphetamine scans, parametric BPND
maps were generated from the summed PET images using BPND=
(CTCCBL)/CCBL. To assess whether steady state conditions were
achieved, [11C]raclopride concentrations were calculated for all eight
frames of each scan. Changes in concentration between frames wereealthy controls F p
ean Range SD
2 21–56 12 0.8 0.46
/8 6.6a 0.04
0 0 – –
0 0 – –
0 0 13.7 o0.001 OCD vs. HC po0.001 OCD vs.
TS po0.001 TS vs. HC ns
.3 0-3 1 57.6 o0.001 OCD vs. HC po0.001 OCD vs.
TS po0.001 TS vs. HC ns
.75 0–3 1 16.1 o0.001 OCD vs. HC po0.001 OCD vs.
TS p=0.02 TS vs. HC ns
D. Denys et al.1426minimal (slopes varied between 0.01 and 0.02) and these changes
were similar across groups and between conditions.
A voxel-based analysis of these parametric images was performed
using SPM2 (Wellcome Trust Center for Neuroimaging, London, UK).
The structural MRI of each subject was normalized to the SPM T1-MRI
template and subsequently this transformation was applied to the co-
registered parametric BPND images. Normalized PET scans were
smoothed using a 5 mm Gaussian ﬁlter resulting in an overall resolu-
tion of 8.5 mm FWHM. To limit the search volume, a functional maskFig. 1 Decreased baseline BPND in TS and OCD (contrast HC4OCD4
Table 2 Areas with signiﬁcant differences in baseline
BPND between groups.
Region MNI-coordinates Cluster size Z-score
Controls4OCD4TS
Left putamen 22 2 2 28 3.52nn
Right putamen 34 2 6 68 3.43nn
Controls4TS
Left putamen 22 0 –2 38 3.60nn
Right putamen 34 2 4 93 3.49nn
Controls4OCD
Left putamen 14 6 8 2 2.60n
npo0.005 uncorrected.
nnpo0.05 FWE corrected.of the striatum was created from the main effect of displacement in
all subjects (baseline BPND4post-amphetamine BPND). In a balanced
design, such a mask is orthogonal with respect to comparisons of
interest (i.e., group differences), and is likely to be more speciﬁc than
anatomical ROIs (Friston et al., 2006). This mask was used in all of the
following analyses. Voxel-wise one-way ANOVA was used to assess the
location of peak differences between groups at baseline, which are
reported at a threshold of po0.05 with Family Wise Error (FWE)
correction for the search volume. Results at po0.005 uncorrected are
reported as trends. Displacement was assessed using a voxel-wise one-
way ANOVA with ΔBPND images, created by subtracting amphetamine
images from baseline images for each subject. Mean baseline BPND
values were added as covariate to the model, to correct for baseline
differences.
Regression analyses were performed for mean symptom severity
scores (YGTSS for TS, YBOCS for OCD) measured during the baseline
scan with baseline BPND as independent variable and severity scores
as dependent variables. Similarly, changes in symptom severity
(difference between YBOCS and YGTSS scores measured immedi-
ately before and 20 min after injection of amphetamine) were
correlated to ΔBPND images.3. Results
3.1. Demographic data
Twelve patients with TS (4 women), 12 patients with OCD (8
women) and 12 healthy control subjects (8 women) partici-
pated in the study. Subject characteristics are provided in
Table 1. Groups were matched for age. For the TS group, theTS) in bilateral putamen. (A) right putamen (B) left putamen.
Fig. 2 Displacement (BPND baseline vs. BPND post-ampheta-
mine) in healthy controls (upper panel), OCD (middle panel)
and TS (lower panel).
1427Dopaminergic activity in Tourette syndrome and obsessive-compulsive disordermean number of current tics at baseline ranged from 4 to 23
(overall mean 1176) with a mean YGTSS score of 1978, andthe mean number of current obsessions or compulsions was
978, with a mean YBOCS severity score of 576. For the OCD
group, the mean YBOCS score was 2476. OCD symptoms were
of the following subtypes: washing (Gerard and Peterson,
2003), aggressive thoughts (Ferrao et al., 2009), forbidden
thoughts (Robertson, 2000), symmetry/ordering (Leckman
et al., 2010) and perfectionism/doubt (Leckman et al., 2010).
3.1.1. Baseline BPND
Differences in baseline BPND between healthy controls, TS
and OCD are listed in Table 2. Omnibus testing revealed
signiﬁcant between-group differences in bilateral putamen
extending into bilateral caudate nucleus, with the highest
baseline BPND values in healthy controls, lowest values in TS
patients and intermediate values in OCD patients (see
Fig. 1). Post hoc testing conﬁrmed that baseline BPND was
signiﬁcantly decreased in TS patients vs. healthy controls in
bilateral putamen. Baseline BPND was decreased in OCD
patients vs. healthy controls in left ventral putamen at
trend level. Baseline BPND differences between OCD and TS
patients were not statistically signiﬁcant.
3.1.2. Amphetamine induced BPND changes
Main effects of amphetamine administration on BPND for all
groups are shown in Fig. 2. Displacement was present in
bilateral striatum (putamen and caudate nucleus), being
most pronounced in healthy controls. A group by displace-
ment effect at trend level in the left ventral caudate (MNI
coordinates: 14 26 2, 8 voxels, Z=2.75, po0.005)
suggested decreased BPND displacement in TS, but these
differences disappeared after correcting for baseline
binding.
3.1.3. Post-amphetamine BPND
An omnibus test showed no signiﬁcant between-group
differences in BPND after administration of amphetamine.
3.1.4. Behavioral response correlates
Following amphetamine administration, tic severity incre-
ased signiﬁcantly in the TS group (p=0.003), with a mean of
3.574.6 points on the YGTSS. This increase in tic severity
correlated positively (ρ=0.85) with displacement in right
ventral caudate at a borderline signiﬁcance level (Fig. 3 and
Table 3). A negative correlation at trend level (p=0.005,
uncorrected) between baseline tic levels and baseline BP
was found in left ventral putamen and right ventral caudate
(Table 3). Finally, a negative correlation (ρ=0.75),
between post-amphetamine YGTSS and post-amphetamine
BPND was found in the right ventral striatum.
In OCD patients, correlations between OCD severity and
baseline BPND, and between changes in YBOCS and displace-
ment were not statistically signiﬁcant.
4. Discussion
The current [11C]raclopride PET study aimed to directly
compare dopaminergic neurotransmission in TS patients
without OCD symptoms, OCD patients without tics and
healthy controls. Both TS and OCD patients showed lower
striatal D2/3 receptor binding at baseline than healthy
controls, although in the OCD group only at trend level.
Fig. 3 (A) Regions showing a signiﬁcant correlation between changes in tic severity and DA release in the TS group. (B) Scatter plot
illustrating correlation between DA release and change in tic severity at MNI coordinate 18 10 8 (right ventral caudate).
Table 3 Correlations between YGTSS scores and BPND for the baseline scan.
Region MNI coordinates Cluster size Z-score
Positive correlation displacement and YGTSS increase
Right ventral caudate 18 10 –8 17 3.51nn
Negative correlation BPND at baseline and YGTSS at baseline
Left ventral putamen 14 14 2 3 2.55n
Negative correlation BPND post-amphetamine and YGTSS post-amphetamine
Right ventral caudate 6 12 0 19 3.60nnn
YGTSS=Yale Global Tic Severity Scale.
npo0.005 uncorrected.
nnpo0.001 uncorrected (p=0.06 FWE corrected).
nnnpo0.05 FWE corrected.
D. Denys et al.1428There were no signiﬁcant differences between amphetamine-
induced changes in BPND between the three groups. Tic
severity in TS patients increased after the amphetamine
challenge, which was correlated with the displacement in
right ventral striatum, whereas no changes in symptom
severity in OCD patients were observed.4.1. Baseline [11C]raclopride binding
The ﬁnding of decreased baseline [11C]raclopride BPND in TS
is in contrast with other PET studies, in which no differences
in binding between TS and controls were found (Singer
et al., 2002; Turjanski et al., 1994; Wong et al., 2008).
Differences in PET scan acquisition, data analysis methodol-
ogy, and patient characteristics may have accounted for
these discrepant ﬁndings. Interestingly, a trend for a
negative correlation between baseline BPND and tic severitywas found, suggesting that decreased baseline BPND is
indeed a pathological feature of TS.
The observation of low baseline striatal [11C]raclopride
binding in OCD at trend level is in line with other SPECT and
PET studies, substantiating the hypothesis of dopaminergic
dysfunction in OCD. Using [123I]iodobenzamide ([123I]IBZM)
SPECT, Denys et al. (2004) showed signiﬁcantly decreased
D2/3 receptor availability in left caudate nucleus within a
group of 10 OCD patients compared with 10 age matched
healthy controls. Schneier et al. (2008) found comparable
striatal D2/3 decrease in 8 predominantly drug-naïve OCD
patients compared with 7 control subjects. Perani et al.
(2008) demonstrated signiﬁcantly decreased striatal [11C]
raclopride binding in dorsal caudate, dorsal putamen and
ventral striatum of 9 drug-naïve OCD patients compared
with 9 controls. D2/3 alterations were more prominent in
ventral striatum.
Decreased baseline [11C]raclopride binding to striatal D2/3
receptors, observed in both TS and OCD, may be due to
1429Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorderseveral mechanisms. It may result from (1) decreased D2/3
receptor density and/or afﬁnity, for instance due to recep-
tor internalization, (2) increased levels of endogenous
dopamine competing with the radiotracer, or (3) a combina-
tion of these phenomena. To assess whether increased
levels of endogenous dopamine are the most plausible
explanation for the lower baseline BPND observed in both
patient groups, a dopamine depletion study should be
conducted, as has been done in patients with schizophrenia
(Abi-Dargham et al., 2009). If conﬁrmed, the tonic/phasic
model of DA release (Grace and Bunney, 1983) could explain
these abnormalities in dopamine neurotransmission in TS.
The single-spike “tonic” ﬁring pattern supplies a constant
low extrasynaptic concentration of DA, whereas burst ﬁring
of the neurons leads to massive DA release into the synapse
which is named the “phasic” response. Amphetamine
induced DA release is believed to mimic this phasic response
(Grace and Bunney, 1983). Synaptic DA concentrations
measured during the baseline scan are thus likely to reﬂect
a combination of both tonic and phasic DA responses during
rest. As such, increased endogenous DA levels at baseline in
both patient groups may be a result of increased phasic
ﬁring at rest, supporting a hyperdopaminergic state that has
been hypothesized to underlie TS and OCD (Denys et al.,
2004; Wong et al., 2008).4.2. Changes in BPND following amphetamine
challenge
Contrary to previous studies, TS patients did not show
increased amphetamine induced DA release compared to
controls. Differences in patient characteristics and metho-
dology may have accounted for these discrepant ﬁndings.
Wong et al. (2008) studied a sample in which the majority of
the TS patients (10 out of 14) were also diagnosed with OCD.
These authors showed that only the subset of TS+OCD
patients display signiﬁcantly increased DA release in the
ventral striatum as compared to controls. This raises the
question if increased DA release might be related to either
TS or OCD, or both. Our sample consisted of OCD patients
without tics and TS patients without OCD to differentiate
between the contributions of either disorder to striatal
dopamine dysregulation. Since our results show no
increased DA release in OCD, it is unlikely that OCD was
responsible for increased DA release in the previous study.
However, we did not ﬁnd increased DA release in the TS
group either, which may have been due to the fact that our
sample was less severely affected, as a result of excluding
patients with co-morbidity. Moreover, TS with co-morbid
OCD is associated with changes in limbic brain areas both
structurally as well as functionally, whereas TS without OCD
is associated with abnormalities in motor areas (Worbe
et al., 2010, 2011). Thus, the ﬁnding of increased ventral
striatal DA release in the study by Wong et al. (2008) may be
speciﬁc for TS patients with associated OCD, which were
excluded from our study.
A second difference between the current study and
previous studies is related to PET scan acquisition protocols.
In these previous studies, amphetamine was administered
5 min before bolus injection of [11C]raclopride and the start
of the emission scan. In the present study a bolus pluscontinuous infusion protocol was used and emission scanning
was performed under steady state conditions. It has been
argued that scanning under steady state conditions is less
susceptible to artifacts due to changes in cerebral blood
ﬂow and washout rate of the tracer (Carson et al., 1997;
Laruelle, 2000), which is preferable when administering
amphetamine as this may affect blood ﬂow. Another advan-
tage of the bolus plus constant infusion protocol is that after
administration of amphetamine subjects stayed outside the
scanner during infusion, which enabled us to record changes
in symptom severity. Amphetamine-induced DA release in
the ventral striatum was related to increased tic severity,
which provides evidence that ventral striatal DA release is
related to the pathophysiology of tics. This ﬁnding is
substantiated by the correlation between tic severity and
dopaminergic tone (at baseline as well as post-ampheta-
mine), but seems to be difﬁcult to reconcile with the low to
normal amphetamine induced DA release in the TS group as
compared to controls. However, it may be argued that only
a small increase in DA may sufﬁce to cause progressive
symptoms, when DA concentrations are already increased at
rest in the TS group.
Tics tend to follow a waxing and waning course, are
partially under voluntary control and tic severity often
decreases after adolescence (1), which led to the hypoth-
esis that tics decrease with increasing prefrontal control
over (abnormal) striatal function (Peterson et al., 2001).
Indeed, cognitive techniques have been successful in con-
trolling tics. Grace et al. (2007) noted that both increased
tonic and phasic DA release can shift the balance from
medial prefrontal cortical (mPFC) control towards limbic
control of goal directed behavior. Increased tonic DA, acting
on D2 receptors, attenuates mPFC activity, whereas
increased phasic DA, acting on D1 receptors enhances limbic
control. In this model, D2 receptor antagonists, the main
pharmacological treatment for TS, increase mPFC control
and may thus restore dopaminergic balance. On the other
hand, increased ventral DA release might result in reinfor-
cement of corticostriatal circuits, facilitating the progres-
sive formation of tics (Groenewegen et al., 2003; Maia and
Frank, 2011; Saka and Graybiel, 2003).4.3. Limitations
Several limitations of our study warrant further discussion.
The control and TS group were not well matched for gender,
with relatively more females in the control group. Gender
differences in both baseline D2 receptor binding as well as
DA release have been observed, and males reportedly to
have relatively higher dopamine release than females
(Munro et al., 2006) and increased baseline D2 binding
(Pohjalainen et al., 1998). However, as the TS group
contained more males than the control group, bias due to
gender would have resulted in increased DA release in the
TS group and increased baseline binding. Moreover, second-
ary analyses including gender as a covariate yielded similar
results (data not shown). Menstrual phase of the female
subjects in our study was not evaluated and might also have
inﬂuenced D2 receptor measurements, as was shown in
female monkeys (Czoty et al., 2009), but not in humans
(Nordstrom et al., 1998). Although our sample was not
D. Denys et al.1430entirely treatment naïve, only one patient had used a D2
receptor antagonist in the past, therefore confounding
effects of previous neuroleptic use are unlikely.
In our study we compared OCD and TS patients, but
excluded TS patients with OCD to investigate the contribu-
tion of either disorder; an additional comparison between a
group of TS patients with and without OCD, controlling for
symptom severity, may further increase our understanding of
the similarities and differences between the two disorders.
Unfortunately, individual differences in impulsivity were
not assessed. Impulsivity may be one of the explanations for
lack of control over tics and compulsive behaviors in TS and
OCD. In addition, impulsivity has been associated with
baseline binding of [11C]raclopride and its displacement
after amphetamine (e.g. Oswald et al., 2007). Neverthe-
less, both YGTSS and YBOCS contain items for control over
tics and compulsions, respectively, and no correlation
between scores on these items and [11C]raclopride binding
or amphetamine induced displacement was observed (data
not shown). Finally, although comparable with earlier
studies, the sample with 12 subjects in each subject group
was modest, so any hypotheses regarding etiology should be
made with caution.4.4. Conclusion
Baseline striatal D2/3 receptor binding in TS and OCD was
decreased in TS and OCD patients, supporting the hypoth-
esis of chronically increased dopaminergic activity in both
disorders. Dopaminergic dysfunction may be a common
pathophysiologic mechanism in TS and OCD, explaining
considerable overlap between the two disorders in terms
of clinical phenomenology.Role of funding source
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